All In Biotech

Drug Trial Radar · NCT04947956

Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma

Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma in China: a Real-world Study

Last checked: Nov 19, 2026Latest source record: Jul 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,000

Planned (sponsor's estimate)

Start

Sep 1, 2021

Primary completion

Sep 1, 2023

Study completion Sep 1, 2025

Sponsor

Lead sponsor
Shanghai Zhongshan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 1, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

Primary liver cancer is the second most common cause of cancer death in China, and hepatocellular carcinoma (HCC) represents more than 80% of liver cancer cases. The majority of HCC cases present at an advanced stage, and are thus not amenable to surgery. Immunotherapies, including PD-1 and PD-L1 inhibitors, alone or combined with other regimens, have shown encouraging clinical activity in unresectable HCC. Camrelizumab, a humanised monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1 and consequently inhibit the immune escape of tumour cells, which has been approved for the second-line treatment of advanced HCC. This observational study aims to evaluate the safety and efficacy of camrelizumab in Chinese unresectable HCC in the real world.

Conditions

  • Unresectable Hepatocellular Carcinoma

Interventions

  • CamrelizumabDrug

    The camrelizumab-based treatment will be determined by the investigator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence of treatment-emergent adverse events (TEAE)Time frame: Up to ~2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.